Local News
Eyewitness Sports
Medical Coverage
Call 12 For Action
Target 12 Investigators
More Details
What's On WPRI
What's On Fox
This Morning Weekend
Experts Online
Online Store
Chopper 12
Station Info

 May 14, 2005
Alzheimer's Drug Trial Offers Mixed Results
Email to a Friend Printer Friendly Version  

Preliminary results of a Phase II clinical trial of the Alzheimer's disease treatment Flurizan did not achieve "statistical significance in all of its primary endpoints," according to an Associated Press report of a statement by drug company Myriad Genetics Inc.

However, the 12-month trial of 207 patients with mild Alzheimer's did yield some encouraging news.

The company on Monday said preliminary data showed a positive trend in those patients taking 800 milligrams of Flurizan twice daily. In patients with mild forms of Alzheimer's, 41 percent showed a slowing of decline into dementia after 12 months, and 29 percent showed a slowing in cognitive decline, compared to those patients taking a placebo, the AP said.

Flurizan is a selective amyloid beta 42 lowering agent. Abeta42 is the primary component of senile plaques that accumulate in the brain of patients with Alzheimer's disease.


Copyright � 2005 ScoutNews, LLC. All rights reserved.

Health News | Health Encyclopedia | Quizzes and Tools | Women's Health | Men's Health | Children's Health | Seniors' Health | Diet, Fitness and Self Image | Sex and Relationships

Health Encyclopedia: Children's Health
Pervasive Developmental Disorders
Otitis Externa
Umbilical Cord Blood
Umbilical Hernia In Infants
Precocious Puberty
Reye's Syndrome
Attention Deficit/Hyperactivity Disorder
Learning Disabilities
Children's Health News
Many Dutch Doctors Support Euthanasia for Terminally Ill Kids
Alzheimer's Drug Trial Offers Mixed Results
Children Safer in Back Seat, Study Confirms
U.S. Child Vaccine Supply Running Low
Progress Slowing Against Child Deaths
Judge Allows Pentagon to Resume Anthrax Vaccinations
Florida Tomato Packing House Linked to 2004 Salmonella Outbreak
Mental Health Problems Plague Kids After Foster Care
Active Ingredient in Marijuana Slows Hardening of Arteries in Mice
Talking About Suicide With Teens Won't Spur Thoughts: Report
Send questions and comments about this website to the .
All content © Copyright 2003-2005 WorldNow, WPRI, WNAC and Associated Press. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.